Saturday, October 31, 2026

USD/EUR Bullish Momentum With A 1% Rise In The Last 21 Sessions

USD/EUR Bullish Momentum With A 1% Rise In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.56% for the last 21 sessions. At 05:08 EST on Thursday, 27 June, USD/EUR (USDEUR) is $0.94.

USD/EUR's yearly highs and lows, it's 5.457% up from its 52-week low and 2.268% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was 0.07%, 0.06%, and 0.26%, respectively.

USD/EUR's highest amplitude of average volatility was 0.29% (last week), 0.29% (last month), and 0.26% (last quarter), respectively.

News about

  • Usd/cnh May follow usd/jpy if it breaks above 160 – societe generale. According to FXStreet on Tuesday, 25 June, "If USD/JPY does break through 160 in the coming days the USD/CNH pair may come along, Chief FX Strategist at Societe Generale Kit Juckes argues.", "If USD/JPY does break through 160 in the coming days, preventing further Yuan weakness would be very difficult indeed."
  • Usd/jpy consolidates near two-month top, remains below 160.00 amid risk of intervention. According to FXStreet on Wednesday, 26 June, "This marks a big divergence in comparison to the Federal Reserve's (Fed) hawkish stance and suggests that the path of least resistance for the USD/JPY pair is to the upside.", "This, in turn, is holding back the USD bulls from placing aggressive bets and capping the upside for the USD/JPY pair. "
  • According to FXStreet on Tuesday, 25 June, "The modest softening of the US Dollar the previous day pushed USD/JPY to an intra-day low of 159.19.", "Monday comments from Japan's top currency official Kanda and Finance Minister Suzuki have also helped to temporarily dampen upward momentum for USD/JPY as it moves back to within touching distance of the year to date high (29thApril, 160.17)."
  • Usd/jpy retreats from 38-year peak, downside potential seems limited. According to FXStreet on Thursday, 27 June, "This, along with the US Treasury bond yields, will influence the USD and drive the USD/JPY pair ahead of the Tokyo Core CPI on Friday. ", "The USD/JPY pair drifts lower during the Asian session on Thursday and erodes a part of the previous day's strong gains to the 160.85-160.90 region, or its highest level since 1986. "
  • Usd/jpy price analysis: hits 38-year high at around 160.80s. According to FXStreet on Wednesday, 26 June, "The USD/JPY is upward biased and extended its gains past the psychological 160.00 barrier for the second time since April 29, when the pair printed a year-to-date (YTD) high of 160.32. ", "The USD/JPY rallied sharply during Wednesday's session after the pair hit a 38-year high past the 160.00 psychological figure, seen as the line of the sand for Japanese authorities and the Japanese Yen to intervene in the FX space. "

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com